Lymphoma

Therapeutic antibodies
#Bispecific Antibodies #Interview #Lymphoma #Oncology

Q&A: Targeting difficult to treat lymphomas with a bispecific antibody

DDW Editor Reece Armstrong speaks to Tahi Ahmadi, MD, PhD, Executive Vice President & Chief Medical Officer, Head of Experimental Medicines, Genmab & Jacqueline Nielsen, PhD, Therapeutic Head, Hematology, AbbVie, about the recommendation and the development of epcoritamab. Earlier this year, the European Medicines Agenecy’s (EMA) Committee for Medicinal Products… Read More

#Cancer Research #Exclusive Content

Tumour microenvironment
#FDA #Lymphoma #Oncology #Phase I trial #Recursion #Solid tumours

RBM39 degrader offers “promising approach” in solid tumours

TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA). REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile. Recursion identified the novel regulatory… Read More

#Cancer Research #News #Regulatory

CAR-T cell therapy
#CAR-T #Cell and gene therapy #Cell therapy #Lymphoma #Oncology

The curative potential of CAR-T cell therapy

Dr Nicholas Siciliano, Co-Founder of Vittoria Biotherapeutics, shares insight on the VIPER-101 trial targeting T-cell lymphoma, the company’s aim to ensure progression free survival and opportunities in this sector.  MT: I understand that your lead programme is moving into the clinic, with POC human data expected in 2024. Can you… Read More

#Cancer Research #Exclusive Content

Monoclonal antibody
#AbbVie #European Commission #Follicular lymphoma #Genmab #Lymphoma #Oncology

Second lymphoma indication approval for Tepkinly in Europe

AbbVie and Genmab’s Tepkinly (epcoritamab) has been granted conditional marketing authorisation by the European Commission (EC) as a monotherapy for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. The approval makes Tepkinly the first subcutaneous T-cell engaging bispecific antibody approved to treat both… Read More

#News #Regulatory

T cell attacking cancer cell
#Cell therapy #Citius Pharmaceuticals #FDA #Lymphoma #Mergers and acquisitions #Oncology

Citius Oncology launches following FDA approval of Lymphir

The US Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl) for the second-line treatment of r/r cutaneous T-cell lymphoma (CTCL), making it Citius Pharma’s first product approved in the US. Lymphir is a novel immunotherapy and the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on… Read More

#Business & Investment #News #Regulatory

Cancer tumour
#4SC #Lymphoma #Oncology #Orphan drugs #Switzerland

Swiss Orphan Drug Status for cutaneous T-cell lymphoma drug

The Swiss Agency for Therapeutic Products (SwissMedic) has granted Orphan Drug Status (ODS) to 4SC’s Kinselby (resminostat) for the treatment of cutaneous T-cell lymphoma (CTCL). In Switzerland, ODS provides privileged status to drugs that show promise for the treatment of rare diseases and qualifies 4SC for benefits including fee reductions… Read More

#News #Regulatory

CAR-T for large B-cell lymphoma
#Allogene Therapeutics #allogeneic cell therapies #Cell therapy #Lymphoma #Oncology #Phase II trial

Phase II trial investigates allogeneic CAR-T for large B-cell lymphoma

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse. The ALPHA3 trial will… Read More

#Cancer Research #News

Scotland
#Lymphoma #Marketing approval authorisation #NHS Scotland #Scottish Medicines Consortium (SMC) #Ulcerative colitis (UC) #Weight loss

Scottish Medicines Consortium advises on six new drugs

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHS Scotland, has published advice on six medicines. 1. Tirzepatide (Mounjaro) was accepted for weight management in adults and is to be used alongside diet and exercise to help people lose weight. It was also given… Read More

#News #Regulatory